Augmenting the randomized controlled trial with real-world data: an interview with Michael Moran

In this podcast, we take a peek behind the paper with lead study author Michael Moran (Pfizer, Berlin, Germany) to discuss some of his research into the possibility of augmenting the randomized controlled trial with real-world data.

Like 0 Comment

Clinical trials are the 'gold standard', established way of gathering evidence to demonstrate the effectiveness of novel therapeutics, however, there are concerns that clinical trials do not fully represent those patients seen in everyday clinical practice.

In this podcast, we take a peek behind the paper with lead study author Michael Moran (Pfizer, Berlin, Germany) to discuss research he was involved in concerning augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma.

In the study, investigators compared the results obtained from 13 clinical trials and 22 real-world studies into the use of tyrosine kinase inhibitors in individuals with metastatic renal cell carcinoma.

Read the full article, published in Future Oncology, here>>


Disclosure:

The opinions expressed in this feature are those of the interviewee/author and do not necessarily reflect the views of The Evidence Base® or Future Science Group.


View our 'In Focus' on the viability of real-world data here>>

Go to the profile of The Evidence Base

The Evidence Base

Community, Future Medicine

The Evidence Base is a community site covering the latest news, opinion and insight into the collection and application of real-world data to real-world problems.
121 Contributions
8 Followers
0 Following

No comments yet.